Serum long noncoding RNA LRB1 as a potential biomarker for predicting the diagnosis and prognosis of human hepatocellular carcinoma

Wang,Zhi‑Feng; Hu,Rui; Pang,Jian‑Min; Zhang,Gui‑Zhen; Yan,Wei; Li,Zeng‑Ning

doi:10.3892/ol.2018.8825

Serum long noncoding RNA LRB1 as a potential biomarker for predicting the diagnosis and prognosis of human hepatocellular carcinoma

Authors:
- Zhi‑Feng Wang
- Rui Hu
- Jian‑Min Pang
- Gui‑Zhen Zhang
- Wei Yan
- Zeng‑Ning Li
View Affiliations

Affiliations: Department of Gastroenterology, The First Hospital of Hebei Medical University, Shijiazhuang, Hebei 050030, P.R. China
Published online on: May 30, 2018 https://doi.org/10.3892/ol.2018.8825
Pages: 1593-1601
Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Hepatocellular carcinoma (HCC) is a type of malignant tumor with a high mortality rate. Long non‑coding RNAs (lncRNAs) serve important roles in cellular processes and gene regulation. Identifying novel prognostic biomarkers is important for the monitoring and treatment of HCC. However, only a limited number of biomarkers with high sensitivity and specificity have been determined and are used in clinical practice. The aim of the present study was to investigate the use of serum lncRNA uc007biz.1 (LRB1) expression levels as a novel non‑invasive biomarker for the monitoring and diagnosis of HCC. The expression levels of LRB1 were detected in 326 patients with HCC and 73 healthy volunteers by using lncRNA expression microarrays and reverse transcription quantitative polymerase chain reaction analysis, and the associations between LRB1 expression and clinical parameters were analyzed. The results indicated that the serum LRB1 levels in patients with HCC were significantly increased compared with healthy volunteers. The serum LRB1 levels were positively associated with α‑fetoprotein (AFP) expression, large tumor sizes, tumor stage (tumor‑node metastasis or Barcelona Clinic Liver Cancer stage) and venous invasion, and were negatively associated with overall survival. Additionally, the use of a combination of LRB1, AFP and des‑γ‑carboxy prothrombin (DCP) markers for the diagnosis of HCC, the diagnostic accuracy was increased compared with using LRB1 alone. LRB1 may act as an important regulator in the progression of HCC, and LRB1 may be considered as a novel biomarker for diagnosis and prediction of prognosis of HCC, additionally complementing the accuracy of AFP and DCP.

View Figures

View References

1	Forner A, Llovet JM and Bruix J: Hepatocellular carcinoma. Lancet. 379:1245–1255. 2012. View Article : Google Scholar : PubMed/NCBI
2	Trépo C, Chan HL and Lok A: Hepatitis B virus infection. Lancet. 384:2053–2063. 2014. View Article : Google Scholar : PubMed/NCBI
3	Lu LC, Cheng AL and Poon RT: Recent advances in the prevention of hepatocellular carcinoma recurrence. Semin Liver Dis. 34:427–434. 2014. View Article : Google Scholar : PubMed/NCBI
4	Wang X, Zhang A and Sun H: Power of metabolomics in diagnosis and biomarker discovery of hepatocellular carcinoma. Hepatology. 57:2072–2077. 2013. View Article : Google Scholar : PubMed/NCBI
5	Zucman-Rossi J, Villanueva A, Nault JC and Llovet JM: Genetic landscape and biomarkers of hepatocellular carcinoma. Gastroenterology. 149:1226–1239. 2015. View Article : Google Scholar : PubMed/NCBI
6	Bruix J, Gores GJ and Mazzaferro V: Hepatocellular carcinoma: Clinical frontiers and perspectives. Gut. 63:844–855. 2014. View Article : Google Scholar : PubMed/NCBI
7	Bruix J, Reig M and Sherman M: Evidence-based diagnosis, staging, and treatment of patients with hepatocellular carcinoma. Gastroenterology. 150:835–853. 2016. View Article : Google Scholar : PubMed/NCBI
8	Frau M, Biasi F, Feo F and Pascale RM: Prognostic markers and putative therapeutic targets for hepatocellular carcinoma. Mol Aspects Med. 31:179–193. 2010. View Article : Google Scholar : PubMed/NCBI
9	Sauzay C, Petit A, Bourgeois AM, Barbare JC, Chauffert B, Galmiche A and Houessinon A: Alpha-foetoprotein (AFP): A multi-purpose marker in hepatocellular carcinoma. Clin Chim Acta. 463:39–44. 2016. View Article : Google Scholar : PubMed/NCBI
10	Cheng J, Wang W, Zhang Y, Liu X, Li M, Wu Z, Liu Z, Lv Y and Wang B: Prognostic role of pre-treatment serum AFP-L3% in hepatocellular carcinoma: Systematic review and meta-analysis. PLoS One. 9:e870112014. View Article : Google Scholar : PubMed/NCBI
11	Schmitt AM and Chang HY: Long noncoding rnas in cancer pathways. Cancer Cell. 29:452–463. 2016. View Article : Google Scholar : PubMed/NCBI
12	Batista PJ and Chang HY: Long noncoding RNAs: Cellular address codes in development and disease. Cell. 152:1298–1307. 2013. View Article : Google Scholar : PubMed/NCBI
13	Mohankumar S and Patel T: Extracellular vesicle long noncoding RNA as potential biomarkers of liver cancer. Brief Funct Genomics. 15:249–256. 2016. View Article : Google Scholar : PubMed/NCBI
14	Bolha L, Ravnik-Glavač M and Glavač D: Long noncoding RNAs as biomarkers in cancer. Dis Markers. 2017:72439682017. View Article : Google Scholar : PubMed/NCBI
15	Misawa A, Takayama K, Urano T and Inoue S: Androgen-induced long noncoding RNA (lncRNA) Socs2-As1 promotes cell growth and inhibits apoptosis in prostate cancer cells. J Biol Chem. 291:17861–1780. 2016. View Article : Google Scholar : PubMed/NCBI
16	Xue S, Li QW, Che JP, Guo Y, Yang FQ and Zheng JH: Decreased expression of long non-coding RNA NBAT-1 is associated with poor prognosis in patients with clear cell renal cell carcinoma. Int J Clin Exp Pathol. 8:3765–3774. 2015.PubMed/NCBI
17	Pandey GK, Mitra S, Subhash S, Hertwig F, Kanduri M, Mishra K, Fransson S, Ganeshram A, Mondal T, Bandaru S, et al: The risk-associated long noncoding RNA NBAT-1 controls neuroblastoma progression by regulating cell proliferation and neuronal differentiation. Cancer Cell. 26:722–737. 2014. View Article : Google Scholar : PubMed/NCBI
18	Bruix J and Sherman M; Practice Guidelines Committee: American association for the study of liver diseases, management of hepatocellular carcinoma. Hepatology. 42:1208–1236. 2005. View Article : Google Scholar : PubMed/NCBI
19	Chun YH, Kim SU, Park JY, Kim DY, Han KH, Chon CY, Kim BK, Choi GH, Kim KS, Choi JS and Ahn SH: Prognostic value of the 7th edition of the AJCC staging system as a clinical staging system in patients with hepatocellular carcinoma. Eur J Cancer. 47:2568–2575. 2011. View Article : Google Scholar : PubMed/NCBI
20	Forner A, Reig ME, de Lope CR and Bruix J: Current strategy for staging and treatment: The BCLC update and future prospects. Semin Liver Dis. 30:61–74. 2010. View Article : Google Scholar : PubMed/NCBI
21	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
22	Subramanian A, Kuehn H, Gould J, Tamayo P and Mesirov JP: Gsea-p: A desktop application for gene set enrichment analysis. Bioinformatics. 23:3251–3253. 2007. View Article : Google Scholar : PubMed/NCBI
23	Singal AG, Pillai A and Tiro J: Early detection, curative treatment, and survival rates for hepatocellular carcinoma surveillance in patients with cirrhosis: A meta-analysis. PLoS Med. 11:e10016242014. View Article : Google Scholar : PubMed/NCBI
24	Poon D, Anderson BO, Chen LT, Tanaka K, Lau WY, van Cutsem E, Singh H, Chow WC, Ooi LL, Chow P, et al: Management of hepatocellular carcinoma in Asia: Consensus statement from the asian oncology summit 2009. Lancet Oncol. 10:1111–1118. 2009. View Article : Google Scholar : PubMed/NCBI
25	Guo Y, Wang J, Zhang L, Shen S, Guo R, Yang Y, Chen W, Wang Y, Chen G and Shuai X: Theranostical nanosystem-mediated identification of an oncogene and highly effective therapy in hepatocellular carcinoma. Hepatology. 63:1240–1255. 2016. View Article : Google Scholar : PubMed/NCBI
26	Cui SX, Zhang YS, Chu JH, Song ZY and Qu XJ: Des-gamma-carboxy prothrombin (DCP) antagonizes the effects of gefitinib on human hepatocellular carcinoma cells. Cell Physiol Biochem. 35:201–212. 2015. View Article : Google Scholar : PubMed/NCBI
27	Hiraoka A, Ishimaru Y, Kawasaki H, Aibiki T, Okudaira T, Toshimori A, Kawamura T, Yamago H, Nakahara H, Suga Y, et al: Tumor Markers AFP, AFP-L3, and DCP in hepatocellular carcinoma refractory to transcatheter arterial chemoembolization. Oncology. 89:167–174. 2015. View Article : Google Scholar : PubMed/NCBI
28	Sun M and Kraus WL: From discovery to function: The expanding roles of long noncoding RNAs in physiology and disease. Endocr Rev. 36:25–64. 2015. View Article : Google Scholar : PubMed/NCBI
29	Knoll M, Lodish HF and Sun L: Long non-coding RNAs as regulators of the endocrine system. Nat Rev Endocrinol. 11:151–160. 2015. View Article : Google Scholar : PubMed/NCBI
30	Okugawa Y, Grady WM and Goel A: Epigenetic alterations in colorectal cancer: Emerging biomarkers. Gastroenterology. 149:1204–1225. 2015. View Article : Google Scholar : PubMed/NCBI
31	Martens-Uzunova ES, Böttcher R, Croce CM, Jenster G, Visakorpi T and Calin GA: Long noncoding RNA in prostate, bladder, and kidney cancer. Eur Urol. 65:1140–1151. 2014. View Article : Google Scholar : PubMed/NCBI
32	Tantai J1, Hu D1, Yang Y1 and Geng J1: Combined identification of long non-coding RNA XIST and HIF1A-AS1 in serum as an effective screening for non-small cell lung cancer. Int J Clin Exp Pathol. 8:7887–7895. 2015.PubMed/NCBI
33	Jin C, Shi W, Wang F, Shen X, Qi J, Cong H, Yuan J, Shi L, Zhu B, Luo X, et al: Long non-coding RNA HULC as a novel serum biomarker for diagnosis and prognosis prediction of gastric cancer. Oncotarget. 7:51763–51772. 2016. View Article : Google Scholar : PubMed/NCBI
34	Amorim M, Salta S, Henrique R and Jerónimo C: Decoding the usefulness of non-coding RNAs as breast cancer markers. J Transl Med. 14:2652016. View Article : Google Scholar : PubMed/NCBI
35	Chauhan R and Lahiri N: Tissue- and serum-associated biomarkers of hepatocellular carcinoma. Biomark Cancer. 8:37–55. 2016.PubMed/NCBI